Tactile Systems (TCMD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue increased 7% year-over-year to $73.2 million, with net income of $4.3 million versus a net loss of $0.1 million in Q2 2023 and adjusted EBITDA up 49% year-over-year to $9.1 million.

• Lymphedema revenues rose 8% to $64.7 million, accounting for 87–88% of revenue, while airway clearance revenues increased 2% to $8.5 million.

• The company is executing on commercial initiatives including technology and workflow investments, next-generation lymphedema platform development, and clinical evidence generation.

• Leadership transition occurred with Sheri Dodd appointed as President and CEO effective July 1, 2024.

• Received FDA 510(k) clearance for the Nimbl lymphedema therapy system, with a limited launch planned for early fall 2024.

Financial highlights

• Gross margin improved to 73.9% from 70.7% year-over-year; non-GAAP gross margin reached 74.3%.

• Operating income increased to $5.8 million; non-GAAP operating income rose to $6.5 million.

• Net income was $4.3 million ($0.18 per diluted share), up from a net loss of $0.1 million; non-GAAP net income increased to $4.8 million.

• Adjusted EBITDA rose to $9.1 million (12% of sales) from $6.1 million (9% of sales) year-over-year.

• Cash and cash equivalents increased to $73.6 million as of June 30, 2024.

Outlook and guidance

• Full-year 2024 revenue guidance revised to $293–$298 million (7–9% growth), down from prior $300–$305 million, due to increased Medicare documentation requirements.

• Adjusted EBITDA guidance raised to $34–$36 million, up from $33–$35 million.

• GAAP gross margin expected at ~73%; operating expenses to increase low double digits due to tech investments.

• Management expects cash, equivalents, and cash flows from operations to be sufficient for at least the next twelve months.

• No change to underlying demand for lymphedema products; technology investments expected to mitigate headwinds.